Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein
- 31 July 2007
- journal article
- research article
- Published by Elsevier BV in Clinical Immunology
- Vol. 124 (1), 26-32
- https://doi.org/10.1016/j.clim.2007.03.544
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicityClinical Immunology, 2005
- From genome to vaccine—new immunoinformatics tools for vaccine designMethods, 2004
- Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2Cancer Cell, 2004
- An In Vitro Human Cell-Based Assay to Rank the Relative Immunogenicity of ProteinsToxicological Sciences, 2004
- Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approachVaccine, 2003
- Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samplesCurrent Medical Research and Opinion, 2003
- Immuno‐informatics: Mining genomes for vaccine componentsImmunology & Cell Biology, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrixVaccine, 1998
- Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cellsEuropean Journal of Immunology, 1989